VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
MEDS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
MEDSDataMEDS AI, Inc.
$1.34$5M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksMEDSCash Flow

DataMEDS AI, Inc. (MEDS) Cash Flow Statement

3Y historyFree accessUpdated daily

Operating cash flow was negative $2.9M in 2026Q3 and free cash flow remained negative in most quarters, with a -0.27 OCF-to-net-income ratio indicating reported profit did not translate into cash generation.

Income StatementBalance SheetCash FlowRatios

MEDS Cash Flow Statement

Annual statement

MEDS Cash Flow Statement

DataMEDS AI, Inc. (MEDS) cash flow statement — 3-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23
Cash from Operations-15.5M-10.86M-1.22M-349.14K
Operating CF Margin %--46.51%-6.76%-
Operating CF Growth %-484.83%-786.13%-250.86%-
Net Income-43.37M-101.27M-6.86M-2.9M
Depreciation & Amortization5.07M3.21M1.11M0
Stock-Based Compensation4.96M54.79M1.08M0
Deferred Taxes0000
Other Non-Cash Items17.31M23.93M93.38K0
Working Capital Changes575.07K8.48M3.34M2.55M
Change in Receivables-1.54M799.77K-40.08K0
Change in Inventory124.8K1.89M-72.36K0
Change in Payables1.63M2.2M-882.32K1.03M
Cash from Investing20.58K-881.53K469.07K0
Capital Expenditures-255.38K-881.53K-377.29K0
CapEx % of Revenue3.33%3.78%2.08%-
Acquisitions00931.37K0
Investments----
Other Investing275.96K0-85.01K0
Cash from Financing11.73M10.75M1.78M350.5K
Debt Issued (Net)11.32M-2.11M620.7K350K
Equity Issued (Net)-326.69K12.86M10K500
Dividends Paid0000
Share Repurchases-327.69K000
Other Financing732.7K01.15M0
Net Change in Cash-3.75M-985.76K1.03M1.36K
Free Cash Flow-15.76M-11.74M-1.6M-349.14K
FCF Margin %-205.22%-50.29%-8.84%-
FCF Growth %-114.88%-632.49%-358.93%-
FCF per Share-3.98-8.27-1.54-0.39
FCF Conversion (FCF/Net Income)0.36x0.11x0.18x0.12x
Interest Paid-1.48M000
Taxes Paid0000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Persistent operating cash burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Net Income Disconnected From Operating Cash

Based on reported figures, DataMEDS AI posted positive net income of $10.6M in 2026Q3 while operating cash flow was negative $2.9M, an OCF-to-net-income ratio of -0.27 that signals the reported profit did not convert into cash.

The gap between net income and operating cash flow is the central issue in this dataset, since the company reports profit in one quarter while consuming cash operationally. Across most quarters the OCF/NI ratio is low or negative, which suggests earnings are being driven by non-cash items or accruals rather than collected revenue. Investors should monitor whether the 2026Q3 profit reflects a one-time or non-cash gain, as it warrants further investigation before the earnings can be treated as durable.

Free Cash Flow Remains Persistently Negative

According to the reported statements, free cash flow was negative in every one of the ten quarters except 2024Q3, reaching -$6.5M in 2025Q4 and -$3.6M in 2026Q1, with FCF margins swinging from roughly -176% to +15%.

The consistent negative free cash flow indicates the business has not yet reached a level of operating scale that funds its own activity. Only the 2024Q3 quarter showed positive FCF of $820.5K, which appears to be an isolated period rather than an emerging trend. The recent quarters show FCF burn persisting at a multi-million dollar run rate, which may indicate continued reliance on external funding, although the data provided does not disclose financing sources.

Minimal Capital Intensity Limits Investment Read

Based on EDBL-style reported figures, CapEx runs between roughly 0.5% and 17% of revenue, with the 2026Q3 quarter showing a small positive investing value against otherwise modest outflows.

Capital expenditure is small in absolute terms and modest relative to revenue, so the business does not appear to be capital intensive. The drivers of cash burn therefore lie in operating costs rather than fixed-asset investment. Because D&A is also modest, the depreciation base offers little signal about asset replacement needs.

Working Capital Swings Mask Underlying Burn

As reported in financial statements, working capital changes ranged from a $4.8M inflow in 2025Q3 to a $2.1M outflow in 2026Q3, indicating that timing of receivables and payables has materially affected quarterly cash results.

Large swings in working capital suggest that quarterly operating cash flow is sensitive to collection and payment timing rather than steady operating performance. The 2025Q3 inflow of $4.8M appears to have temporarily offset operating losses, which means the underlying burn may be larger than headline quarterly figures imply. Investors should monitor whether these inflows reverse, as reversals could further pressure cash position.

Cumulative Earnings Versus Cash Reality

Based on reported figures, cumulative net income across the ten quarters is negative, while cumulative operating cash flow is also negative, with stock-based compensation of $27.8M and $25.7M in two quarters inflating the gap between accounting and cash results.

Both cumulative net income and cumulative operating cash flow are negative, so the company has not generated cash from operations over the period despite occasional profitable quarters. Large non-cash stock-based compensation charges in 2025Q1 and 2025Q3 appear to account for much of the difference between reported losses and cash burn. This suggests the cash economics are weaker than the accounting results alone would indicate, which warrants further investigation into the sustainability of the cost base.

Stock Compensation Obscures True Cash Burn

Based on reported figures, stock-based compensation of $27.8M in 2025Q1 and $25.7M in 2025Q3 may be masking the operating cash cost base, since non-cash charges of this scale can make reported losses look smaller than the cash the business consumes.

Stock-based compensation is excluded from operating cash flow, so the cash burn figures shown here already reflect that add-back, yet the equity dilution it implies is not captured in the cash line. Investors should monitor how much of the operating cost base is paid in shares rather than cash, since this affects both per-share value and the company's need for future external funding. The data provided does not disclose share count changes, so the dilution impact warrants further investigation.

MEDS — Frequently Asked Questions

Quick answers to the most common questions about buying MEDS stock.

How much cash does DataMEDS AI, Inc. (MEDS) generate from operations?

DataMEDS AI, Inc. (MEDS) generated $-10.9M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is DataMEDS AI, Inc.'s free cash flow?

DataMEDS AI, Inc. (MEDS) reported negative free cash flow of $11.7M in 2025, indicating capital requirements exceeded cash from operations.

What is DataMEDS AI, Inc.'s capital expenditure (CapEx)?

DataMEDS AI, Inc. (MEDS) spent $0.9M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.